Hôpital Bichat-Claude-Bernard

Running trials

• Not yet recruiting

  A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk

  NCT07900633· Phase 3· Eli Lilly and Company· Source

• Not yet recruiting

  A Study of Ivonescimab Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants with Unresectable Stage III NSCLC

  2026-526300-67-00· Phase 3· Summit Therapeutics Inc.· Source

• Not yet recruiting

  Efficacy of Upadacitinib Re-induction Therapy in Patients With Ulcerative Colitis Who Lost Response to 30 mg Maintenance Dose

  NCT07700446· Phase 4· Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives· Source

• Recruiting

  Feasibility of the Application of a New Six-month Treatment for Multidrug-resistant Tuberculosis (MDR-TB) Patients in France (FAST-MDR)

  NCT07486024· Phase 3· Assistance Publique - Hôpitaux de Paris· Source

• Recruiting

  Virus-associated Tumour Microenvironment

  NCT06471296· Assistance Publique - Hôpitaux de Paris· Source

• Not yet recruiting

  Evaluation of a New Strategy to Approach the Transgender Sex Worker Populations and Their Clients for Access to a Preventive Sexual Health System Through the ORTIF Digital Teleconsultation Solution

  NCT07516691· Assistance Publique - Hôpitaux de Paris· Source

• Not yet recruiting

  CABOTEGRAVIR/LENACAPAVIR DUAL LONG ACTING THERAPY (COHORT IMEA 074)

  NCT07402044· Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba· Source

• Recruiting

  Efficacy of Chronotherapeutic Combination for Major Depressive Episode With Insomnia

  NCT07120880· Phase 3· Assistance Publique - Hôpitaux de Paris· Source

• Recruiting

  Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer

  NCT07001618· Phase 2· Gustave Roussy, Cancer Campus, Grand Paris· Source

• Recruiting

  A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma

  NCT07219173· Phase 2· Eli Lilly and Company· Source

• Recruiting

  CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis

  NCT07207811· Phase 3· Novo Nordisk A/S· Source

• Active, not recruiting

  Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

  NCT07037433· Phase 3· Amgen· Source

• Recruiting

  Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

  NCT07037459· Phase 3· Amgen· Source

• Recruiting

  Interventional, multicenter, open-label, randomized, non-comparative trial evaluating the safety, in terms of HBV virological control, of 2 antiviral treatment relief strategies, in patients co-infected with the HIV-1 and HBV viruses

  2023-508634-34-00· Phase 2· Inserm· Source

• Recruiting

  MODULO

  NCT06774872· Phase 3· Centre De Recherches Et D'Etudes Sur La Pathologie Tropicale Et Le Sida· Source

• Active, not recruiting

  The Effect of Hedia Diabetes Assistant on TiMe-in-range in People With Type 1 Diabetes and Sub-Optimal Glycemic Control in France - A Randomised Controlled Trial.

  NCT06819306· Hedia ApS· Source

• Enrolling by invitation

  Chest CT Biomarkers as Prognostic Predictors in SSc-ILD

  NCT06472362· Royal Brompton & Harefield NHS Foundation Trust· Source

• Recruiting

  Quality of Life Related to the Care of Women Living With HIV During the Perinatal Period

  NCT06666530· Assistance Publique - Hôpitaux de Paris· Source

• Recruiting

  CARE1 Pragmatic Clinical Trial

  NCT06364631· Phase 3· Gustave Roussy, Cancer Campus, Grand Paris· Source

• Recruiting

  Phase II Trial of ART + Dual bNAbs vs. ART + Placebo During Primary HIV-1 Infection-impact on Post-ART Control

  NCT05300035· Phase 2· ANRS, Emerging Infectious Diseases· Source

• Recruiting

  Contribution of the CEST Sequence in the Characterization of Radionecrosis of Brain Metastases of Pulmonary Origin

  NCT05977803· Assistance Publique - Hôpitaux de Paris· Source

• Recruiting

  ctDNA in CRC Patients Undergoing Curative-intent Surgery for Liver Metastases

  NCT05787197· GERCOR - Multidisciplinary Oncology Cooperative Group· Source

• Recruiting

  Prevention Of Sudden Cardiac Death After Myocardial Infarction by Defibrillator Implantation

  NCT05665608· Charite University, Berlin, Germany· Source

• Recruiting

  Omega Gastric Bypass (150cm) Compared to the Roux-en-Y Gastric Bypass (YOMEGA-2 Multicentric Trial)

  NCT06057597· Assistance Publique - Hôpitaux de Paris· Source

• Recruiting

  Workshops and Exchange Groups for Laryngectomized Patients

  NCT06077643· Assistance Publique - Hôpitaux de Paris· Source

• Recruiting

  The ReTAVI Prospective Observational Registry

  NCT05601453· Institut für Pharmakologie und Präventive Medizin· Source

• Recruiting

  Repertoire and Properties of Anti-drug Antibodies Involved in Immediate Hypersensitivity in the Operating Room

  NCT05420935· Assistance Publique - Hôpitaux de Paris· Source

• Active, not recruiting

  An Observational Study to Assess Change in Disease Activity and Use of Upadacitinib Tablets in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis in Real World

  NCT05669794· AbbVie· Source

• Active, not recruiting

  A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)

  NCT05668988· Phase 3· Dizal Pharmaceuticals· Source

• Active, not recruiting

  A Cohort Study of Use of Doravirine (DOR) Based Regimens in Clinical Practice in Europe DoRavirine Europe Real World/

  NCT05421806· NEAT ID Foundation· Source

• Recruiting

  Cardioverter DefIbriIlator PlacEMent for priMary Prevention of Sudden cArdiac Death in Patients Older Than 70 Years

  NCT05373940· Assistance Publique - Hôpitaux de Paris· Source

• Active, not recruiting

  Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

  NCT04821622· Phase 3· Pfizer· Source

• Active, not recruiting

  A Phase 3 Study of Zalunfiban in Subjects With ST-elevation MI

  NCT04825743· Phase 3· CeleCor Therapeutics· Source

• Recruiting

  National Cohort of Patients Co-infected With Hepatitis B and Delta Viruses

  NCT04166266· ANRS, Emerging Infectious Diseases· Source

• Active, not recruiting

  A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer

  NCT04165317· Phase 3· Pfizer· Source

• Active, not recruiting

  Evaluation of the Safety and Efficacy of TLD in Patients with COPD

  NCT03639051· Nuvaira, Inc.· Source

• Active, not recruiting

  A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

  NCT03893955· Phase 1· AbbVie· Source

• Active, not recruiting

  Maintaining or Stopping Immunosuppressive Therapy in Patients With ANCA Vasculitis and End-stage Renal Disease

  NCT03323476· Phase 3· Centre Hospitalier Departemental Vendee· Source

• Active, not recruiting

  PERIGON Pivotal Trial

  NCT02088554· Medtronic Cardiac Surgery· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• HIV6 recruiting
• Heart failure3 recruiting
• Lung cancer3 recruiting
• Obesity3 recruiting
• Amyloidosis1 recruiting
• Asthma1 recruiting
• Colorectal cancer1 recruiting
• Coronary artery disease1 recruiting
• Depression1 recruiting
• Head and neck cancer1 recruiting
• Hepatitis B1 recruiting
• Insomnia1 recruiting
• Kidney cancer1 recruiting
• Systemic sclerosis (scleroderma)1 recruiting
• Tuberculosis1 recruiting
• Type 2 diabetes1 recruiting
• Ulcerative colitis1 recruiting

Closed trials

• Recruiting

  A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases

  NCT06570798· Phase 2· Amgen· Source

• Completed

  Pilot study, open label, multicenter, evaluating dual antiretroviral therapy with long-acting cabotegravir/lenacapavir IMEA 069 - CALENDULA

  2024-516028-33-01· Phase 3· Inst Medecine Epidemiologie Appliquee· Source

• Completed

  Becoming HIV-Exposed, Uninfected Children Born to HIV-Positive Mothers Followed at Bichat Claude Bernard Hospital

  NCT06666543· Assistance Publique - Hôpitaux de Paris· Source

• Completed

  Vaginal Self-sampling for Detecting High-risk Human Papillomavirus Cervical Infection in Patients With Immune-mediated Inflammatory Diseases

  NCT06302725· Assistance Publique - Hôpitaux de Paris· Source

• Completed

  Morbidity, Mortality And Risk Factors of Mpox in HIV Negative High Risk Sexual Health Clinic Attenders and People Living With HIV

  NCT05965427· NEAT ID Foundation· Source

• Terminated

  Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis

  NCT06097260· Phase 2· Pliant Therapeutics, Inc.· Source

• Completed

  An Observational Study to Assess Change in Disease Activity and Treatment Patterns of Upadacitinib When Given Alone or Co-Administered With Methotrexate in Adult Participants With Active Psoriatic Arthritis

  NCT05616871· AbbVie· Source

• Completed

  Use of MULTIplex PCR, procalcitonin and the appearance of sputum to reduce the duration of antibiotic therapy during severe COPD EXAcerbation: a trial controlled, randomized, open, in parallel groups, multicenter

  2024-511896-13-00· Phase 4· Assistance Publique Hopitaux De Paris· Source

• Completed

  Genes Modulating the Severity of Aortic Aneurysms (MSF1-TGFBR2)

  NCT05146375· French Cardiology Society· Source

• Completed

  Contribution of Canine Detection in the Diagnostic Strategy of High-risk Prostate Cancer (Prostate-K9-Detect)

  NCT05558735· Assistance Publique - Hôpitaux de Paris· Source

• Terminated

  A Study to Assess the Efficacy and Safety of Namilumab in Participants With Chronic Pulmonary Sarcoidosis

  NCT05314517· Phase 2· Kinevant Sciences GmbH· Source

• Completed

  VALVOSOFT® Pivotal Study

  NCT05235568· Cardiawave SA· Source

• Completed

  Study of Interference Between Oral Anticoagulants and Heparin During Ablation of Atrial Fibrillation (AF) or Left Atrial Tachycardia (GAD) by Catheter.

  NCT05802576· Assistance Publique - Hôpitaux de Paris· Source

• Terminated

  Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

  NCT04868877· Phase 1/2· Merus B.V.· Source

• Completed

  Tofacitinib in Adult Patients With Moderate to Severe Ulcerative Colitis

  NCT04424303· Pfizer· Source

• Completed

  A Study of Oral Upadacitinib Tablets to Assess Treatment Patterns, Achievement of Treatment Targets and Maintenance of Response in Adult Participants With Moderate to Severe Rheumatoid Arthritis

  NCT04497597· AbbVie· Source

• Completed

  Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy

  NCT04447118· Phase 3· Jiangsu HengRui Medicine Co., Ltd.· Source

• Completed

  Cardiac MRI in Front Line for the Diagnosis of Coronary Artery Disease as the Etiology of Left Ventricular Dysfunction

  NCT03231189· Assistance Publique - Hôpitaux de Paris· Source

• Completed

  Abatacept vs Tocilizumab for the Treatment of RA in TNF Alpha Inhibitor Inadequate Responders

  NCT03227419· Phase 4· Lille Catholic University· Source

• Completed

  Sleep Apnea and Atrial Fibrillation Recurrence

  NCT02906839· Assistance Publique - Hôpitaux de Paris· Source

• Completed

  Assessing Effectiveness of Adalimumab for Treating Ulcerative Colitis in Real Life Conditions

  NCT02738125· AbbVie· Source

• Completed

  A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

  NCT01848561· AbbVie· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Bladder cancer35 works · 1 trial
• Idiopathic pulmonary fibrosis27 works · 1 trial
• Insomnia24 works · 1 trial
• Ankylosing spondylitis12 works · 0 trials
• Amyloidosis11 works · 1 trial
• Myocarditis11 works · 0 trials
• Sarcoidosis7 works · 1 trial
• Dermatomyositis and polymyositis (myositis)4 works · 0 trials
• ANCA-associated vasculitis4 works · 1 trial